NPPB and hydrops fetalis: Our results are in line with those of DAPA-HF (−196 ± 2387 vs. 101 ± 2944, p < 0.001) [5] as opposed to the DEFINE-HF trial, during which the use of dapagliflozin over 12 weeks did not affect mean NT-proBNP, despite increasing the proportion of patients experiencing clinically meaningful improvements in HF-related health status [26].